Zelquistinel

Zelquistinel (GATE-251, formerly AGN-241751) is a novel, orally bioavailable, small-molecule positive allosteric modulator of the N-methyl-D-aspartate (NMDA) glutamate receptor, currently in Phase 2b clinical development for major depressive disorder (MDD) under the sponsorship of Syndeio Biosciences (operating as Gate Neurosciences). The compound is the third-generation successor to the tetrapeptide rapastinel (GLYX-13) and the dipeptide apimostinel (NRX-1074), sharing a common mechanism of NMDA receptor positive modulation but replacing the peptide scaffold with a spirocyclic 2,5-diazaspiro[3.4]octane (beta-lactam) core that confers oral bioavailability approaching 100 percent in preclinical species, a plasma half-life of approximately 1.2 to 2.1 hours, and approximately 1000-fold greater potency than rapastinel on a weight basis.

Zelquistinel binds to a unique extracellular site on the NMDA receptor that is distinct from the glutamate agonist site, the glycine co-agonist site, the phencyclidine channel-blocking site, and the polyamine modulatory site. The compound does not displace radioligands at any of these four canonical sites and shows no significant activity across a panel of 80 receptors, ion channels, and monoamine transporters. Mechanistically, zelquistinel acts through a long-distance allosteric pathway: extracellular binding reduces intracellular calcium-dependent inactivation (CDI) of the NMDA receptor channel, thereby enhancing NMDA receptor current in an activity-dependent manner. This mechanism has been demonstrated through experiments showing that replacement of the intracellular calcium chelator EGTA with the fast chelator BAPTA abolishes zelquistinel potentiation, and that removal of the NR1 C-terminal intracellular domain or infusion of calmodulin-blocking peptide similarly eliminates the modulatory effect. Subtype selectivity studies reveal potent enhancement at NR2A-containing (EC50 approximately 9.9 nM) and NR2C-containing (EC50 approximately 9.7 nM) receptors, with a larger ceiling enhancement at NR2B-containing receptors (EC50 approximately 35.0 nM) and no effect at NR2D-containing receptors.

The pharmacological profile produces a characteristic biphasic, inverted-U dose-response relationship: potentiation of NMDA receptor-mediated calcium influx at concentrations of 0.3 to 60 nM and mild inhibition at concentrations exceeding 100 nM. In preclinical behavioral models, single oral doses of zelquistinel at 30 micrograms per kilogram produce rapid antidepressant-like effects in the forced swim test (onset within one hour) that are sustained for more than seven days, and rescue social approach behavior in the chronic social defeat model at efficacy comparable to ketamine at 10 mg/kg subcutaneous. The compound enhances long-term potentiation (LTP) in both medial prefrontal cortex and hippocampal Schaffer collateral-CA1 pathways, with metaplastic enhancement persisting for at least two weeks after a single dose. Critically, zelquistinel produces no motor impairment on the rotarod test at doses 100-fold above the antidepressant-effective dose and no psychotomimetic symptoms as measured by validated clinical scales in human subjects.

In Phase 1 clinical evaluation, single ascending oral doses from 100 micrograms to 50 mg were well tolerated in 60 healthy volunteers, with dose-proportional pharmacokinetics, rapid absorption, significant cerebrospinal fluid penetration, and no clinically significant adverse events, vital sign changes, electrocardiographic abnormalities, or psychotomimetic symptoms. A Phase 2a exploratory trial in 251 patients with major depressive disorder demonstrated statistically significant reductions in Montgomery-Asberg Depression Rating Scale (MADRS) scores at the two highest once-weekly oral doses (reductions of 9.5 and 10.6 points versus 7.7 points with placebo at week three). The U.S. Food and Drug Administration granted Fast Track designation for zelquistinel in MDD in July 2018. As of the date of this monograph, a Phase 2b confirmatory trial is actively recruiting under Syndeio Biosciences sponsorship. Additional preclinical research has demonstrated durable relief of core behavioral deficits in three mouse models of autism spectrum disorder, and dose-dependent reversal of phencyclidine-induced hyperlocomotion, expanding the potential therapeutic scope beyond depression.

This monograph reviews the chemistry, structural class, and synthesis of zelquistinel; the dual extracellular-intracellular allosteric mechanism in molecular and electrophysiological detail; the comprehensive preclinical and human pharmacokinetic record; the clinical evidence base in major depressive disorder; sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five NMDA receptor-targeting antidepressant candidates (rapastinel, apimostinel, esketamine, REL-1017, and AV-101) against zelquistinel on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from chemical suppliers; investigators should obtain analytical confirmation of identity and purity on every lot.